Kazia Therapeutics Inc. rose over 6% in pre-market trading after the company shared encouraging early-stage data for its cancer drug NDL2. The treatment showed strong tumor reduction in multiple preclinical models, especially when combined with existing immunotherapy drugs, boosting investor optimism around its future potential.